Newsletter | February 6, 2026

02.06.26 -- Corporate Spin-Offs And NewCos: Unlocking Value In Biopharma Innovation

FEATURED ARTICLE

Corporate Spin-Offs And NewCos: Unlocking Value In Biopharma Innovation

Rising R&D costs and shifting priorities are driving biopharma companies to use spin-offs and NewCos to advance overlooked assets. These models enable focused innovation, independent funding, and long-term value creation through sharper execution and flexible risk management.

INDUSTRY INSIGHTS

CDMO Selection: Three Essentials For New Drug Developers

Finding the right development partner is often the biggest hurdle in moving a molecule from lab to clinic. Explore key considerations that help teams choose the right fit for a successful partnership.

Securing A Treatment Through Grit And Collaboration

Learn how one family defied the odds — bringing a lifesaving gene therapy from idea to treatment in just 14 months after a devastating rare disease diagnosis.

A Risk-Based Approach To Design, Operations, And Grades

Explore how Annex 1 applies to low bioburden DS manufacturing and promotes a risk-based approach to contamination control that balances regulatory compliance with operational efficiency.

Five Key Considerations For Choosing The Right ERP

Selecting an Enterprise Resource Planning (ERP) system is a pivotal decision for life sciences organizations, influencing regulatory compliance, operational efficiency, and long-term growth.

Building An Analytics Culture In Clinical Development

Unveil how embracing fast and flexible clinical analytics can help you address clinical questions and provide real-time insights into data issues as they arise.

Headcount Solutions Without Co-Employment Risk

This company delivers compliant, on‑site scientific teams that support operations without adding headcount or exposing organizations to co‑employment risk.
 

CONTRIBUTE TO LIFE SCIENCE LEADER

Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.